Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Amgen Inc.NASDAQ: AMGN

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures grows, but more slowly than its trailing trend

Q2 FY2026 capital expenditures of $513M (cash outflow) rose 39.0% year over year, behind the +63.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 27.9% from the prior quarter. Over 3 fiscal years it compounded at +25.7% a year.

Context

  • Capital expenditures amounted to 5.1% of revenue in FY2025, up 1.8 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +39.0% toward the trailing-twelve-month pace of +63.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$513M-27.9% QoQ
Last fiscal yearDec 2025
-$1.86B+69.5% YoY
LTMJun 2026
-$2.3B+63.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.0%——
1 year+69.5%——
3-year CAGR+25.7%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.86B) USD
Year-over-year change
-69.5%

Capital Expenditures vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +63.6% is the highest of 10, against a peer median of -12.1%.
  • Capital expenditures amounts to 6.0% of revenue for AMGN, versus a peer median of 5.3%.
AMGN Competitors
Capital Expenditures for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$8.03B USD-26.9%+38.0%10.1%
JNJJohnson & JohnsonLTM Sep 2026$5.57B USD+8.6%+6.4%5.6%
AZNAstraZeneca PLCLTM Sep 2026$4.01B USD-28.0%+31.9%6.5%
MRKMerck & Co., Inc.LTM Jun 2026$3.9B USD+2.4%-2.1%5.9%
NVSNovartis AGLTM Jun 2026$2.57B USD-35.5%-11.4%4.6%
PFEPfizer Inc.LTM Jun 2026$2.42B USD-12.1%-6.7%3.8%
AMGNAmgen Inc.LTM Jun 2026$2.3B USD+63.6%+25.7%6.0%
GSKGSK plcLTM Jun 2026£1.76B GBP-42.4%-2.2%5.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$1.34B USD+1.4%+5.5%2.7%
ABBVAbbVie Inc.LTM Jun 2026$1.3B USD+24.2%+20.4%2.0%
Peer median (excluding AMGN) —-12.1%+5.5%5.3%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.89B6.55B6.72B4.09B7.71B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
Deferred Income Tax(453M)(1.2B)(1.27B)(1.23B)(721M)
Stock-Based Compensation341M401M431M530M494M
Change in Working Capital(1.19B)(733M)(484M)2.37B(1.98B)
Accounts Receivables(429M)(746M)(1.02B)441M(2.68B)
Inventory(165M)(742M)491M2.53B886M
Accounts Payables(69M)154M(402M)312M428M
Other Working Capital(531M)601M442M(920M)(616M)
Other Non-Cash Items1.28B1.28B(991M)141M(715M)
Operating Cash Flow9.26B9.72B8.47B11.49B9.96B
Capital Expenditures(880M)(936M)(1.11B)(1.1B)(1.86B)
Acquisitions (Net)(2.69B)(3.73B)(26.99B)0(53M)
Purchases of Investments(8.9B)(2.59B)(1M)00
Sales of Investments13.23B1.22B1.67B00
Other Investing Activities(35M)(12M)225M50M(32M)
Investing Cash Flow733M(6.04B)(26.2B)(1.05B)(1.94B)
Debt Repayment795M6.62B25.68B(4.26B)(5.68B)
Common Stock Issued00000
Common Stock Repurchased(4.98B)(6.36B)0(200M)0
Dividends Paid(4.01B)(4.2B)(4.56B)(4.83B)(5.12B)
Other Financing Activities(78M)(103M)(72M)(124M)(52M)
Financing Cash Flow(8.27B)(4.04B)21.05B(9.42B)(10.86B)
Effect of Forex Changes00000
Net Change in Cash1.72B(360M)3.32B1.03B(2.84B)
Free Cash Flow8.38B8.79B7.36B10.39B8.1B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.